Table 2.
Overview table with mortality rates and hazard ratios per cause of death outcome and exposure group
| Outcome | Reference Individuals | All EGID | Eosinophilic Gastritis | Eosinophilic Gastroenteritis (small intestine) | Eosinophilic Colitis |
|---|---|---|---|---|---|
| All-cause Death | |||||
| N | 11,719* | 2429* | 292* | 694* | 1756* |
| Events | 1240 | 314 | 54 | 94 | 196 |
| Person-years (*1000) | 113.09 | 22.96 | 2.37 | 7.11 | 16.9 |
| IR (%) [95% CI] | 10.96 [10.36–11.59] | 13.68 [12.21–15.28] | 22.83 [17.15–29.79] | 13.22 [10.68–16.18] | 11.60 [10.03–13.34] |
| IR diff. [95% CI] | 0 (ref.) | 2.71 [1.08–4.34] | 11.82 [5.71–17.93] | 2.26 [-0.49–5] | 0.63 [-1.1–2.37] |
| Model 1 aHR [95% CI] | 1 (ref.) | 1.19 [1.05–1.35] | 1.81 [1.33–2.47] | 1.53 [1.21–1.92] | 1.00 [0.86–1.17] |
| Model 2 aHR [95% CI] | 1 (ref.) | 1.17 [1.04–1.33] | 1.81 [1.32–2.48] | 1.50 [1.18–1.89] | 0.99 [0.85–1.16] |
| Cardiovascular death | |||||
| N | 11,686 | 2422 | 290 | 691 | 1753 |
| Events | 439 | 98 | 22 | 26 | 57 |
| Person-years (*1000) | 113.06 | 22.95 | 2.36 | 7.11 | 16.89 |
| IR (%) [95% CI] | 3.88 [3.53–4.26] | 4.27 [3.47–5.20] | 9.31 [5.83–14.09] | 3.66 [2.39–5.36] | 3.37 [2.56–4.37] |
| IR diff. [95% CI] | 0 (ref.) | 0.39 [-0.53–1.31] | 5.44 [1.53–9.35] | -0.23 [-1.68–1.23] | -0.51 [-1.46–0.44] |
| Model 1 aHR [95% CI] | 1 (ref.) | 1.03 [0.83–1.29] | 1.88 [1.15–3.08] | 1.23 [0.80–1.89] | 0.82 [0.62–1.09] |
| Model 2 aHR [95% CI] | 1 (ref.) | 1.02 [0.82–1.28] | 1.94 [1.18–3.20] | 1.22 [0.79–1.88] | 0.82 [0.62–1.09] |
| Cancer death | |||||
| N | 11,686 | 2422 | 290 | 691 | 1753 |
| Events | 313 | 87 | 17 | 27 | 52 |
| Person-years (*1000) | 113.06 | 22.95 | 2.36 | 7.11 | 16.89 |
| IR (%) [95% CI] | 2.77 [2.47–3.09] | 3.79 [3.04–4.68] | 7.19 [4.19–11.52] | 3.80 [2.50–5.53] | 3.08 [2.30–4.04] |
| IR diff. [95% CI] | 0 (ref.) | 1.02 [0.17–1.88] | 4.43 [1–7.87] | 1.03 [-0.44–2.49] | 0.31 [-0.58–1.2] |
| Model 1 aHR [95% CI] | 1 (ref.) | 1.33 [1.05–1.69] | 2.76 [1.55–4.93] | 1.77 [1.14–2.75] | 1.05 [0.77–1.42] |
| Model 2 aHR [95% CI] | 1 (ref.) | 1.33 [1.05–1.69] | 2.80 [1.56–5.02] | 1.73 [1.11–2.70] | 1.05 [0.78–1.42] |
| Cancer death | |||||
| N | 11,686 | 2422 | 290 | 691 | 1753 |
| Events | 488 | 129 | 15 | 41 | 87 |
| Person-years (*1000) | 113.06 | 22.95 | 2.36 | 7.11 | 16.89 |
| IR (%) [95% CI] | 4.32 [3.94–4.72] | 5.62 [4.69–6.68] | 6.35 [3.55–10.47] | 5.77 [4.14–7.82] | 5.15 [4.12–6.35] |
| IR diff. [95% CI] | 0 (ref.) | 1.3 [0.26–2.35] | 2.04 [-1.2–5.28] | 1.45 [-0.36–3.26] | 0.83 [-0.31–1.98] |
| Model 1 aHR [95% CI] | 1 (ref.) | 1.24 [1.02–1.51] | 1.21 [0.69–2.14] | 1.61 [1.13–2.29] | 1.13 [0.90–1.44] |
| Model 2 aHR [95% CI] | 1 (ref.) | 1.20 [0.98–1.46] | 1.17 [0.65–2.10] | 1.55 [1.08–2.22] | 1.10 [0.86–1.39] |
EGID eosinophilic gastrointestinal disorders distal to the esophagus, IR incidence rate, aHR adjusted hazard ratios
Model 1 adjusts for age at EGID diagnosis (first biopsy), sex, county of residence, and calendar year. Model 2 adds adjustments for education, eczema, allergy, asthma, and eosinophilic esophagitis
*The number of study participants was slightly higher in the overall mortality than in the cause-specific mortality analyses. The follow-up of the cause-specific mortality analyses ended on 31 December 2016 and hence did not include EGID patients diagnosed in 2017 and their controls